Clinical Trial Update: Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT) [Phase 2]

View source ↗

Summary

This document provides an update on a Phase 2 clinical trial evaluating ruxolitinib for bronchiolitis obliterans syndrome following allogeneic hematopoietic cel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchiolitis Obliterans Syndrome

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Other Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING